Early studies with a non-selective kinase inhibitor targeting multiple CDKs (1/2/4/7), VEGFR and PDGFR, called ZK 304709, displayed significant anti-tumor activity (G2 phase cell cycle arrest and apoptosis) in BON1 xenograft tumors [124]. This evidence concerns the gene KDR and neoplasm.